Clinical Trials Directory

Trials / Completed

CompletedNCT05453344

DEXCOM ONE: Continuous Glucose Monitoring in the Real World, Utility of Sustained High Alerts

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
112 (actual)
Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to gather feedback on a new continuous glucose monitor (CGM), called DEXCOM One. Unlike some other CGMs which allow a low (hypoglycaemic) and a high (hyperglycaemic) glucose alarm to be set, the DEXCOM One sensor has the unique feature of the 'Sustained Hyperglycaemic Alert', where the alarm is only activated if the glucose is above a certain threshold for a pre-specified amount of time. International consensus guidance states that people with diabetes should aim for 70% time in the range 3.9-10 mmol/L. After meals there is usually a rise in blood glucose, so it is not unexpected for the glucose to go above 10 mmol/L for a short time even if the insulin dose already given before a meal is correct. Therefore, people with a high glucose alarm set at 10 mmol/L on their GCM may unnecessarily inject extra insulin and risk a low blood glucose. However, DEXCOM One's Sustained Hyperglycaemic Alert would only notify patients if their blood sugar was high for a prolonged period, and so may reflect a time when it would be genuinely advantageous to inject more insulin. The aim of this single-centre, non-randomised, observational study is to gather experience from a range of users to assess the utility of this unique attribute, and the optimal settings. We aim to recruit 80-100 patients, and each participant's involvement is in 2 phases; for the first 3 months DEXCOM One sensors will be used, and for months 4-6 there will be the option of continuing to use the DEXCOM One sensors with the addition of a FitBit to track physical activity.

Conditions

Interventions

TypeNameDescription
DEVICEDexCom oneProvision of DexCom One for glucose monitoring

Timeline

Start date
2022-08-10
Primary completion
2023-08-16
Completion
2023-08-16
First posted
2022-07-12
Last updated
2024-06-04

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT05453344. Inclusion in this directory is not an endorsement.